08/06/2018 15:38:01

SOITEC : INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES FORMING THE SHARE CAPITAL

Related content
21 Jun - 
SOITEC ANNOUNCES THE SUCCESS OF ITS OFFERING OF BONDS C..
21 Jun - 
SOITEC LAUNCHES AN OFFERING OF BONDS CONVERTIBLE INTO A..
19 Jun - 
SOITEC : AVAILABILITY OF THE 2017-2018 REGISTRATION DOC..

Bernin, on June, 8th 2018

INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS

AND SHARES FORMING THE SHARE CAPITAL

(Article L. 233-8 II of the French Commercial Code and article 223-16 of the General Regulation of the French financial markets authority (A.M.F))

Name and address of the Company:

SOITEC

Parc Technologique des Fontaines

Chemin des Franques

38190 BERNIN

(Code ISIN FR0013227113)

Statement date

Total number of shares forming the share capital

Total number of voting rights

05/31/2018 31,636,932 Number of theoretical (gross) voting rights (1) : 34,893,680
Number of exercisable (net) voting rights (2) : 34,619,238

(1)

The total number of theoretical voting rights (or "gross" voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares without voting rights (in the present case, the 5,077 treasury shares held as of 05/31/2018 and the 269,365 preference shares of 0.10€ par value each existing on 05/31/2018) and after taking into account the number of shares entitled to double voting rights on 05/31/2018.

(2) The total number of exercisable voting rights (or "net" voting rights) is calculated after taking into account the number of shares entitled to double voting rights on 05/31/2018, and after deduction of the shares without voting rights (in the present case, the 5,077 treasury shares held as of 05/31/2018 and the 269,365 preference shares of 0.10€ par value each existing on 05/31/2018).

Download the press release in PDF


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: SOITEC via Globenewswire

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
BIOLIFE4D Modifies its Regulation A+ (Mini-IPO) Offering Due to Popular Demand
2
Lexicon Pharmaceuticals Announces Positive 52-Week Results From Sotagliflozin inTandem2 Study Presented at ADA 2018 and Published in Diabetes Care
3
Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes
4
Zealand Pharma presents two dasiglucagon milestone studies at the 78th Scientific Sessions of the American Diabetes Association (ADA)
5
Zealand Pharma presents two dasiglucagon milestone studies at the 78th Scientific Sessions of the American Diabetes Association (ADA)

Related stock quotes

Soitec 77.45 2.4% Stock price increasing

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
24 June 2018 04:39:56
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180619.1 - EUROWEB7 - 2018-06-24 05:39:56 - 2018-06-24 04:39:56 - 1000 - Website: OKAY